[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:hypochondroplasia:fibroblast-growth-factor-receptor-3":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Hypochondroplasia","Fibroblast Growth Factor Receptor 3",4,[8,16,22,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07126262","A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to \u003C 36 Months",[12],"Phase 2","RECRUITING","2026-08-26T02:19:04.543908Z","2026-05-05T02:43:28.339822Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06410976","Prospective Clinical Assessment Study in Children With Hypochondroplasia",[],"2026-08-26T02:17:16.126291Z","2026-05-13T02:55:06.489808Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT07393373","Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:18:58.958025Z","2026-06-16T05:54:07.881623Z",{"nct_id":30,"title":31,"phases":32,"status":26,"updated_at":34,"content_modified":35},"NCT06873035","An Interventional Study of Infigratinib in Children With Hypochondroplasia",[33],"Phase 2\u002FPhase 3","2026-08-26T02:15:29.632183Z","2026-06-16T05:54:07.784396Z"]